Grapiprant

Research use only, not for human use.

A novel EP4 antagonist; an analgesic and anti-inflammatory drug in the piprant class that was approved for Veterinary Medicine for the control of pain and inflammation.

A novel EP4 antagonist; an analgesic and anti-inflammatory drug in the piprant class that was approved for Veterinary Medicine for the control of pain and inflammation associated with osteoarthritis (OA) in dogs.Pain Phase 2 Clinical(In Vivo):Grapiprant (0-50 mg/kg; oral administration; every 24 hours; for 9 months; beagles) is safe for dogs by long-term oral administration. Efficacy of Grapiprant in the treatment of dogs with osteoarthritis needs to be evaluated in other studies.

——

Grapiprant (0-50 mg/kg; oral administration; every 24 hours; for 9 months; beagles) is safe for dogs by long-term oral administration. Efficacy of Grapiprant in the treatment of dogs with osteoarthritis needs to be evaluated in other studies . Animal Model:36 beagles of both sexes (9-month-old) Dosage:0 mg/kg, 1 mg/kg, 6 mg/kg, or 50 mg/kg Administration:Oral administration; every 24 hours; for 9 months Result:Long-term oral administration was safe for dogs.

CJ-023423 | AAT-007

GPCR/G Protein

Prostaglandin Receptor

Prostaglandin Receptor

Neurological Disease

Pain

415903-37-6

491.6052

C26H29N5O3S

>98% (HPLC)

10 mM in DMSO

O=C(NCCC1=CC=C(C=C1)N2C(CC)=NC3=C(N=C(C=C32)C)C)NS(C4=CC=C(C=C4)C)(=O)=O

Benzenesulfonamide, N-[[[2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl]amino]carbonyl]-4-methyl-

(-20℃)

With Ice Pack

≥ 2 years